Response by type | Definitions |
Hematologic | |
Complete | WBC <10 × 109/L |
Basophils <5% | |
No myelocytes, promyelocytes, myeloblasts in the differential | |
Platelet count <450 × 109/L | |
Spleen nonpalpable | |
Cytogenetic* | |
Major | Complete: No Ph+ metaphases or <1% BCR::ABL1-positive nuclei of ≥200 nuclei on FISH |
Partial: 1 to 35% Ph+ metaphases | |
Minor | 36 to 65% Ph+ metaphases |
Minimal | 66 to 95% Ph+ metaphases |
None | >95% Ph+ metaphases |
Molecular¶ | |
MR4.5 | Detectable disease with ratio of BCR::ABL1 to ABL1 (or other housekeeping genes) ≤0.0032% (≥4.5 log reduction) on the international scale (IS) or Undetectable disease in cDNA with ≥32,000 ABL1 transcripts |
MR4 | Detectable disease with ratio of BCR::ABL1 to ABL1 ≤0.01% (≥4 log reduction) on the IS or Undetectable disease in cDNA with ≥10,000 ABL1 transcripts |
MR3 | Detectable disease with ratio of BCR::ABL1 to ABL1 (or other housekeeping genes) ≤0.1% (≥3 log reduction) on the IS |
WBC: white blood cell; Ph+: Philadelphia chromosome positive; FISH: fluorescence in situ hybridization; IS: international scale.
* Chromosome banding analysis of ≥20 bone marrow cell metaphases is necessary to determine the degree of cytogenetic response. If marrow cell metaphases cannot be obtained or evaluated by chromosome banding analysis, the definition of CCyR may be based on interphase fluorescence in situ hybridization of blood cells, provided that it is performed with BCR::ABL1 extrasignal, dual color, dual fusion, or in situ hybridization probes, and that ≥200 nuclei are scored.
¶ Molecular responses are, in general, reported on the evaluation of blood, not marrow samples. For a standardized assessment of the MolR, the conversion of each laboratory datum to the international scale (IS) is recommended, to correct for the variability of the assays in different laboratories. To allow for intra-laboratory variations, a fluctuation of less than one log requires confirmation.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟